AbCellera Biologics (ABCL) Operating Expenses (2020 - 2023)
AbCellera Biologics (ABCL) has disclosed Operating Expenses for 4 consecutive years, with $75.2 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, Operating Expenses rose 26.82% year-over-year to $75.2 million, compared with a TTM value of $75.2 million through Sep 2024, down 70.99%, and an annual FY2024 reading of $343.6 million, up 24.84% over the prior year.
- Operating Expenses was $75.2 million for Q4 2023 at AbCellera Biologics, up from $61.5 million in the prior quarter.
- Across five years, Operating Expenses topped out at $91.6 million in Q1 2022 and bottomed at $6.8 million in Q1 2020.
- Average Operating Expenses over 4 years is $49.5 million, with a median of $56.0 million recorded in 2021.
- The sharpest move saw Operating Expenses soared 558.9% in 2021, then decreased 15.9% in 2023.
- Year by year, Operating Expenses stood at $47.1 million in 2020, then rose by 22.59% to $57.8 million in 2021, then rose by 2.67% to $59.3 million in 2022, then rose by 26.82% to $75.2 million in 2023.
- Business Quant data shows Operating Expenses for ABCL at $75.2 million in Q4 2023, $61.5 million in Q3 2023, and $61.4 million in Q2 2023.